TAF1 differentially enhances androgen receptor transcriptional activity via its N-terminal kinase and ubiquitin-activating and -conjugating domains

Molecular Endocrinology

Volumn 24, Issue 4, 2010, Pages 696-708

  Tavassoli, Peyman ^a,b   Wafa, Latif A ^a,b   Cheng, Helen ^b   Zoubeidi, Amina ^a,b   Fazli, Ladan ^b   Gleave, Martin ^a,b   Snoek, Robert ^b   Rennie, Paul S ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b VANCOUVER PROSTATE CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; GLUTATHIONE TRANSFERASE; PHOSPHOTRANSFERASE; POLYUBIQUITIN; PROSTATE SPECIFIC ANTIGEN; SMALL INTERFERING RNA; TATA BINDING PROTEIN ASSOCIATED FACTOR; TATA BINDING PROTEIN ASSOCIATED FACTOR 1; UBIQUITIN CONJUGATING ENZYME; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; CASTRATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPRECIPITATION; NEOPLASM; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; TISSUE MICROARRAY; TRANSACTIVATION; TRANSCRIPTION INITIATION; UBIQUITINATION;

BLOTTING, WESTERN; CELL LINE, TUMOR; HUMANS; IMMUNOPRECIPITATION; MALE; PROSTATIC NEOPLASMS; PROTEIN BINDING; RECEPTORS, ANDROGEN; RNA, SMALL INTERFERING; TATA-BINDING PROTEIN ASSOCIATED FACTORS; TRANSCRIPTION FACTOR TFIID; TRANSCRIPTIONAL ACTIVATION; TWO-HYBRID SYSTEM TECHNIQUES;

EID: 77950398628     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2009-0229     Document Type: Article

References (71)

1. Heinlein CA, Chang C 2004 Androgen receptor in prostate cancer. Endocr Rev 25:276-308
2. Litvinov IV, De Marzo AM, Isaacs JT 2003 Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling? J Clin Endocrinol Metab 88:2972-2982
3. Tsai MJ, O'Malley BW 1994 Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem 63:451-486
4. Heinlein CA, Chang C 2002 Androgen receptor (AR) coregulators: an overview. Endocr Rev 23:175-200
5. Horwitz KB, Jackson TA, Bain DL, Richer JK, Takimoto GS, Tung L 1996 Nuclear receptor coactivators and corepressors. Mol Endocrinol 10:1167-1177
6. Fu M, Wang C, Reutens AT, Wang J, Angeletti RH, Siconolfi-Baez L, Ogryzko V, Avantaggiati ML, Pestell RG 2000 p300 and p300/cAMP-response element-binding protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivation. J Biol Chem 275:20853-20860
7. Gnanapragasam VJ, Leung HY, Pulimood AS, Neal DE, Robson CN 2001 Expression of RAC 3, a steroid hormone receptor coactivator in prostate cancer. Br J Cancer 85:1928-1936
8. Wang X, Yeh S, Wu G, Hsu CL, Wang L, Chiang T, Yang Y, Guo Y, Chang C 2001 Identification and characterization of a novel androgen receptor coregulator ARA267-α in prostate cancer cells. J Biol Chem 276:40417-40423
9. Choudhry MA, Ball A, McEwan IJ 2006 The role of the general transcription factor IIF in androgen receptor-dependent transcription. Mol Endocrinol 20:2052-2061
10. 2-terminal transactivation domain of the human androgen receptor: binding kinetics for interactions with TFIIF and SRC-1a. Biochemistry 47:3352-3359
11. Evans RM 1988 The steroid and thyroid hormone receptor superfamily. Science 240:889-895
12. Roy AK, Chatterjee B 1995 Androgen action. Crit Rev Eukaryot Gene Expr 5:157-176
13. Agoulnik IU, Weigel NL 2006 Androgen receptor action in hormone-dependent and recurrent prostate cancer. J Cell Biochem 99:362-372
14. Chang CS, Kokontis J, Liao ST 1988 Structural analysis of complementary DNA and amino acid sequences of human and rat androgen receptors. Proc Natl Acad Sci USA 85:7211-7215
15. Lubahn DB, Joseph DR, Sullivan PM, Willard HF, French FS, Wilson EM 1988 Cloning of human androgen receptor complementary DNA and localization to the X chromosome. Science 240:327-330
16. Trapman J, Klaassen P, Kuiper GG, van der Korput JA, Faber PW, van Rooij HC, Geurts van Kessel A, Voorhorst MM, Mulder E, Brinkmann AO 1988 Cloning, structure and expression of a cDNA encoding the human androgen receptor. Biochem Biophys Res Commun 153:241-248
17. Hirst M, Ho C, Sabourin L, Rudnicki M, Penn L, Sadowski I 2001 A two-hybrid system for transactivator bait proteins. Proc Natl Acad Sci USA 98:8726-8731
18. Ray MR, Wafa LA, Cheng H, Snoek R, Fazli L, Gleave M, Rennie PS 2006 Cyclin G-associated kinase: a novel androgen receptor-interacting transcriptional coactivator that is overexpressed in hormone refractory prostate cancer. Int J Cancer 118:1108-1119
19. Wafa LA, Cheng H, Rao MA, Nelson CC, Cox M, Hirst M, Sadowski I, Rennie PS 2003 Isolation and identification of L-dopa decarboxylase as a protein that binds to and enhances transcriptional activity of the androgen receptor using the repressed transactivator yeast two-hybrid system. Biochem J 375:373-383
20. Albright SR, Tjian R 2000 TAFs revisited: more data reveal new twists and confirm old ideas. Gene 242:1-13
21. Martel LS, Brown HJ, Berk AJ 2002 Evidence that TAF-TATA box-binding protein interactions are required for activated transcription in mammalian cells. Mol Cell Biol 22:2788-2798
22. Verrijzer CP, Tjian R 1996 TAFs mediate transcriptional activation and promoter selectivity. Trends Biochem Sci 21:338-342
23. Dikstein R, Ruppert S, Tjian R 1996 TAFII250 is a bipartite protein kinase that phosphorylates the base transcription factor RAP74. Cell 84:781-790
24. II250 subunit of TFIID has histone acetyltransferase activity. Cell 87:1261-1270
25. Pham AD, Sauer F 2000 Ubiquitin-activating/conjugating activity of TAFII250, a mediator of activation of gene expression in Drosophila. Science 289:2357-2360
26. Li HH, Li AG, Sheppard HM, Liu X 2004 Phosphorylation on Thr-55 by TAF1 mediates degradation of p53: a role for TAF1 in cell G1 progression. Mol Cell 13:867-878
27. Allende-Vega N, McKenzie L, Meek D 2008 Transcription factor TAFII250 phosphorylates the acidic domain of Mdm2 through recruitment of protein kinase CK2. Mol Cell Biochem 316:99-106
28. II250 to derepress RNA polymerase II transcription in vitro. J Biol Chem 276:25582-25588
29. Léveillard T, Wasylyk B 1997 The MDM2 C-terminal region binds to TAFII250 and is required for MDM2 regulation of the cyclin A promoter. J Biol Chem 272:30651-30661
30. Siegert JL, Rushton JJ, Sellers WR, Kaelin Jr WG, Robbins PD 2000 Cyclin D1 suppresses retinoblastoma protein-mediated inhibition of TAFII250 kinase activity. Oncogene 19:5703-5711
31. Cai C, Hsieh CL, Shemshedini L 2007 c-Jun has multiple enhancing activities in the novel cross talk between the androgen receptor and Ets variant gene 1 in prostate cancer. Mol Cancer Res 5:725-735
32. Gaughan L, Logan IR, Neal DE, Robson CN 2005 Regulation of androgen receptor and histone deacetylase 1 by Mdm2-mediated ubiquitylation. Nucleic Acids Res 33:13-26
33. Narayanan BA, Narayanan NK, Davis L, Nargi D 2006 RNA interference-mediated cyclooxygenase-2 inhibition prevents prostate cancer cell growth and induces differentiation: modulation of neuronal protein synaptophysin, cyclin D1, and androgen receptor. Mol Cancer Ther 5:1117-1125
34. Heemers HV, Tindall DJ 2007 Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev 28:778-808
35. Wafa L 2007 Identification and characterization of proteins that interact with the androgen receptor to modulate its activity. In: Pathology and laboratory medicine. Vancouver: University of British Columbia; 185-210
36. Wafa LA, Palmer J, Fazli L, Hurtado-Coll A, Bell RH, Nelson CC, Gleave ME, Cox ME, Rennie PS 2007 Comprehensive expression analysis of L-dopa decarboxylase and established neuroendocrine markers in neoadjuvant hormone-treated versus varying Gleason grade prostate tumors. Hum Pathol 38:161-170
37. II250 by a retroposed homolog that is expressed in human spermatogenesis. Hum Mol Genet 11:2341-2346
38. O'Brien T, Tjian R 2000 Different functional domains of TAFII250 modulate expression of distinct subsets of mammalian genes. Proc Natl Acad Sci USA 97:2456-2461
39. Read JT, Rahmani M, Boroomand S, Allahverdian S, McManus BM, Rennie PS 2007 Androgen receptor regulation of the versican gene through an androgen response element in the proximal promoter. J Biol Chem 282:31954-31963
40. Miranda M, Sorkin A 2007 Regulation of receptors and transporters by ubiquitination: new insights into surprisingly similar mechanisms. Mol Interv 7:157-167
41. Burgdorf S, Leister P, Scheidtmann KH 2004 TSG101 interacts with apoptosis-antagonizing transcription factor and enhances androgen receptor-mediated transcription by promoting its monoubiquitination. J Biol Chem 279:17524-17534
42. Belz T, Pham AD, Beisel C, Anders N, Bogin J, Kwozynski S, Sauer F 2002 In vitro assays to study protein ubiquitination in transcription. Methods 26:233-244
43. Taplin ME, Balk SP 2004 Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence. J Cell Biochem 91:483-490
44. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL 2004 Molecular determinants of resistance to antiandrogen therapy. Nat Med 10:33-39
45. Rennie PS, Nelson CC 1998 Epigenetic mechanisms for progression of prostate cancer. Cancer Metastasis Rev 17:401-409
46. Sirotnak FM, She Y, Khokhar NZ, Hayes P, Gerald W, Scher HI 2004 Microarray analysis of prostate cancer progression to reduced androgen dependence: studies in unique models contrasts early and late molecular events. Mol Carcinog 41:150-163
47. Tilley WD, Lim-Tio SS, Horsfall DJ, Aspinall JO, Marshall VR, Skinner JM 1994 Detection of discrete androgen receptor epitopes in prostate cancer by immunostaining: measurement by color video image analysis. Cancer Res 54:4096-4102
48. Locke JA, Guns ES, Lubik AA, Adomat HH, Hendy SC, Wood CA, Ettinger SL, Gleave ME, Nelson CC 2008 Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 68:6407-6415
49. Mohler JL 2008 A role for the androgen-receptor in clinically localized and advanced prostate cancer. Best Pract Res Clin Endocrinol Metab 22:357-372
50. Sadar MD, Hussain M, Bruchovsky N 1999 Prostate cancer: molecular biology of early progression to androgen independence. Endocr Relat Cancer 6:487-502
51. Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim EE, Hopwood VL, Pathak S, von Eschenbach AC, Chung LW 1994 Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 54:2577-2581
52. Ueda T, Mawji NR, Bruchovsky N, Sadar MD 2002 Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells. J Biol Chem 277:38087-38094
53. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, Klocker H 1994 Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 54:5474-5478
54. Shang Y, Myers M, Brown M 2002 Formation of the androgen receptor transcription complex. Mol Cell 9:601-610
55. Nazareth LV, Weigel NL 1996 Activation of the human androgen receptor through a protein kinase A signaling pathway. J Biol Chem 271:19900-19907
56. Sadar MD 1999 Androgen-independent induction of prostate-specific antigen gene expression via cross-talk between the androgen receptor and protein kinase A signal transduction pathways. J Biol Chem 274:7777-7783
57. Cheng H, Snoek R, Ghaidi F, Cox ME, Rennie PS 2006 Short hairpin RNA knockdown of the androgen receptor attenuates ligand-independent activation and delays tumor progression. Cancer Res 66:10613-10620
58. Rodriguez MS, Desterro JM, Lain S, Midgley CA, Lane DP, Hay RT 1999 SUMO-1 modification activates the transcriptional response of p53. EMBO J 18:6455-6461
59. Poukka H, Karvonen U, Janne OA, Palvimo JJ 2000 Covalent modification of the androgen receptor by small ubiquitin-like modifier 1 (SUMO-1). Proc Natl Acad Sci USA 97:14145-14150
60. Mohler JL, Gregory CW, Ford 3rd OH, Kim D, Weaver CM, Petrusz P, Wilson EM, French FS 2004 The androgen axis in recurrent prostate cancer. Clin Cancer Res 10:440-448
61. Andrews NC, Faller DV 1991 A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res 19:2499
62. Kokubo T, Swanson MJ, Nishikawa JI, Hinnebusch AG, Nakatani Y 1998 The yeast TAF145 inhibitory domain and TFIIA competitively bind to TATA-binding protein. Mol Cell Biol 18:1003-1012
63. II250). J Biol Chem 279:26257-26265
64. II250: a transcription toolbox. J Cell Sci 114:2895-2902
65. Irvin JD, Pugh BF 2006 Genome-wide transcriptional dependence on TAF1 functional domains. J Biol Chem 281:6404-6412
66. Zhou ZX, Kemppainen JA, Wilson EM 1995 Identification of three proline-directed phosphorylation sites in the human androgen receptor. Mol Endocrinol 9:605-615
67. Zhu Z, Becklin RR, Desiderio DM, Dalton JT 2001 Identification of a novel phosphorylation site in human androgen receptor by mass spectrometry. Biochem Biophys Res Commun 284:836-844
68. Lin HK, Altuwaijri S, Lin WJ, Kan PY, Collins LL, Chang C 2002 Proteasome activity is required for androgen receptor transcriptional activity via regulation of androgen receptor nuclear translocation and interaction with coregulators in prostate cancer cells. J Biol Chem 277:36570-36576
69. Xu K, Shimelis H, Linn DE, Jiang R, Yang X, Sun F, Guo Z, Chen H, Li W, Chen H, Kong X, Melamed J, Fang S, Xiao Z, Veenstra TD, Qiu Y 2009 Regulation of androgen receptor transcriptional activity and specificity by RNF6-induced ubiquitination. Cancer Cell 15:270-282
70. Kaiser P, Flick K, Wittenberg C, Reed SI 2000 Regulation of transcription by ubiquitination without proteolysis: Cdc34/SCF(Met30)-mediated inactivation of the transcription factor Met4. Cell 102:303-314
71. Le Cam L, Linares LK, Paul C, Julien E, Lacroix M, Hatchi E, Triboulet R, Bossis G, Shmueli A, Rodriguez MS, Coux O, Sardet C 2006 E4F1 is an atypical ubiquitin ligase that modulates p53 effector functions independently of degradation. Cell 127:775-788